IRCT20210130050179N6RecruitingPhase 2
Clinical investigation of the safety and effectiveness of Excilia Hair strengthening and ani hair loss Lotion in improving male pattern androgenic hair loss
Zist orchid pharmed Company0 sites25 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 55 years (—)
- Sex
- Male
Inclusion Criteria
- •Male aged 18-55 years
- •General health
- •Hair Loss Status II, III, IV Based on Norwood Scale
- •Voluntary participation and signing written informed consent
Exclusion Criteria
- •Chronic active scalp disease other than hair loss
- •Using any prescribed drug or OTC for hair loss within the past 3 months
- •Documented sensitivity to formulation components
- •Any severe weight loss or strict diet therapy during the study
- •Oral or topical treatment of minoxidil within 6 months before entering the study.
Investigators
Similar Trials
Recruiting
Phase 2
Clinical investigation of Topaz hair strengthening solution in preventing and improving hair lossHair loss.Nonscarring hair loss, unspecifiedL65.9IRCT20210130050179N5Qeshm Rojin Company20
Completed
Not Applicable
A clinical study of the Safety and effectiveness of Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) treatment for the palliation of painful bone metastasesJPRN-UMIN000012441Department of Orthopaedic Surgery, Kochi Medical School, Kochi University25
Active, not recruiting
Phase 1
Clinical study to evaluate the efficacity and safety of octagam®10% in idiopathic thrombocytopenic purpura in adults - N/AEUCTR2005-003552-35-FROctapharma AG116
Completed
Not Applicable
Clinical study for the safety and effectiveness of the use of Perfectha® Derm lidocaine in the treatment of medium wrinklesISRCTN20356582Sinclair Pharma70
Not yet recruiting
Not Applicable
Clinical research of the effect and the safety with 0.1% bromfenac sodium hydrate ophthalmic solution and 0.1% betamethasone sodium phosphate ophthalmic, otic and nasal solution in patients with diabetic macular edemaJPRN-UMIN000026201Diabetes Center Tokyo Womens Medical University School of Medicine20